GRAIL company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

grail.com

Founded Year

2015

Stage

Acquired | Acquired

Total Raised

$2.005B

Valuation

$0000 

About GRAIL

GRAIL combines high-intensity sequencing, computer science, and large population-scale clinical studies to develop a blood test for early-stage cancer detection. GRAIL has developed Galleri, a multi-cancer early detection test that can detect over 50 types of cancers.On September 21st, 2020, GRAIL was acquired by Illumina at a valuation of $8B. At the time of the acquisition, Illumina, a prior investor in Grail owned 14.5% of the company’s outstanding shares which made the effective purchase price for Grail closer to $7 billion.

GRAIL Headquarter Location

1525 O'Brien Drive

Menlo Park, California, 94025,

United States

650-542-0372

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing GRAIL

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GRAIL is included in 8 Expert Collections, including Digital Health.

D

Digital Health

12,917 items

Startups recreating how healthcare is delivered

D

Digital Health 150

300 items

2019's cohort of the most promising digital health startups transforming the healthcare industry

C

Cancer

3,710 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'

M

Medical Devices

8,594 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

2,394 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

O

Omics

1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

GRAIL Patents

GRAIL has filed 99 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • DNA
  • Genetics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/30/2018

3/15/2022

Molecular biology, DNA, Biotechnology, Genetics, Molecular biology techniques

Grant

Application Date

3/30/2018

Grant Date

3/15/2022

Title

Related Topics

Molecular biology, DNA, Biotechnology, Genetics, Molecular biology techniques

Status

Grant

Latest GRAIL News

Comprehensive Study Establishes Cost of Late Detection and Treatment of Cancer

May 12, 2022

05/12/2022 | 11:01am EDT Message : *Required fields An analysis of 2 million Medicare beneficiaries establishes the cost of cancer by stage and time since diagnosis for 17 common cancers. The later the stage at diagnosis, the higher the cost, and this cost difference lasts for at least five years after diagnosis. Earlier diagnosis and treatment of cancer saves not just lives, but also a significant amount of money. BEVERLY HILLS, Calif., May 12, 2022 /PRNewswire/ -- Cancer is the second leading cause of death and cancer care costs $1 trillion annually. PHAR, a leading health services research consultancy, and GRAIL, a healthcare company whose mission is to detect cancer early when it can be cured, conducted an analysis of the Surveillance, Epidemiology and End Results (SEER) registry and linked Medicare data. Using these linked data sources, researchers systematically estimated the annual cost of care for 17 invasive cancers. The analysis was published in Current Medical Research and Opinion in April 2022. The study establishes a single resource for healthcare professionals, researchers, and payers in addition to providing a starting point to measure the benefit of early cancer detection. Dr. Michael S. Broder, MD, MSHS, President of PHAR, notes, "Now, any agency or organization hoping to reduce the cost of cancer knows what the current cost is. That's never been analyzed and presented in this way before." He continues, "The study establishes that later diagnosis means higher costs for years to come." Diagnosis at a later stage is up to seven times more expensive than diagnosis at an earlier stage, and that cost remains higher for at least five years after diagnosis. The study was conducted in collaboration with GRAIL, Inc., developer of the Galleri test, which uses artificial intelligence and machine learning to analyze DNA data from a blood draw to detect more than 50 types of cancers. This technology can reduce cancer burden worldwide and improve patient outcomes; PHAR's in-depth cost analysis allows for the scientific community to measure by how much. About: Founded in 2004, PHAR is a clinically focused health services research consultancy. PHAR combines rigorous methodology with extensive clinical expertise to conduct high quality health economics and outcomes research for life sciences companies, specialty societies, and not-for-profit health advocacy groups. For more information about PHAR, visit www.pharllc.com . GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. GRAIL, LLC, is a wholly-owned subsidiary of Illumina, Inc. (NASDAQ: ILMN). For more information, please visit www.grail.com . View original content: https://www.prnewswire.com/news-releases/comprehensive-study-establishes-cost-of-late-detection-and-treatment-of-cancer-301545657.html

  • When was GRAIL founded?

    GRAIL was founded in 2015.

  • Where is GRAIL's headquarters?

    GRAIL's headquarters is located at 1525 O'Brien Drive, Menlo Park.

  • What is GRAIL's latest funding round?

    GRAIL's latest funding round is Acquired.

  • How much did GRAIL raise?

    GRAIL raised a total of $2.005B.

  • Who are the investors of GRAIL?

    Investors of GRAIL include Illumina, ARCH Venture Partners, CPP Investments, Qiming Venture Partners, Decheng Capital and 27 more.

  • Who are GRAIL's competitors?

    Competitors of GRAIL include Freenome, Owlstone Medical, Inivata, Thrive Earlier Detection, X-Zell and 11 more.

You May Also Like

Freenome Logo
Freenome

Freenome is an AI genomics biotechnology company in South San Francisco, California. By using a blood test, Freenome can help detect and treat cancer quickly and efficiently.

20/20 GeneSystems Logo
20/20 GeneSystems

20/20 GeneSystems has developed, validated, and undergone clinical testing of a blood test for the early detection of lung cancer. The test measures a panel of tumor biomarkers and utilizes a proprietary algorithm to combine the biomarker values to generate a unitary risk score.

Owlstone Medical Logo
Owlstone Medical

Owlstone Medical is a diagnostics company developing a breathalyzer for disease detection. Its Breath Biopsy platform enables early detection across multiple cancers and a range of other conditions. Breath Biopsy can also be used to enable precision medicine, ensuring that the right drug is given to the right patient at the right time, helping to improve patient outcomes and reduce healthcare costs.

OncoTAB Logo
OncoTAB

OncoTAB's technology was used to develop a blood test, Agkura Personal Score, which aids breast cancer detection in women with dense breast tissue.

A
Accuragen

Accuragen has developed a high-sensitivity next-generation sequencing-based system for the detection of cancer mutations in minuscule concentrations of circulating cell-free DNA (cfDNA) in blood. The Company's technology addresses the significant barriers associated with harnessing the information contained in cfDNA by combining proprietary techniques in molecular biology and computational algorithm for error suppression. With Accuragen's technology, nanogram quantities of highly-fragmented cfDNA can be amplified more than 1000-fold, and a panel of tens to hundreds of cancer-related genes can be screened with a sensitivity at the single-digit molecular level.

L
Liquid Genomics

Liquid Genomics monitors patient therapy via blood-based molecular testing. Blood based testing is used to detect and quantify cancer gene mutations with high sensitivity using Digital PCR and or Allele Specific Blocker PCR for blood or tissue.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.